• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BICALUTAMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • BICALUTAMIDE chembl:CHEMBL409 ApprovedAntineoplastic

    Alternate Names:

    COSUDEX
    ICI-176334
    BICALUTAMIDE
    ICI176,334-1
    CALUTIDE
    KALUMID
    CASODEX
    CASODEX®
    ZD7054
    CALUTIDE®
    BICALUTAMIDUM
    ICI 176334
    BICALUTAMIDA
    pubchem.compound:2375
    rxcui:83008
    drugbank:01128
    chemidplus:90357-06-5
    chembl:CHEMBL409

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Year of Approval 1995
    Drug Class antineoplastic agents
    (4 More Sources)

    Publications:

    Wang et al., 1998, Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor., Biochem. Pharmacol.
    Bouchal et al., 2002, The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP., Biochem. Pharmacol.
    Laufer et al., 1999, Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer., Urology
    Hara et al., 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome., Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Chang et al., 1999, Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells., Proc. Natl. Acad. Sci. U.S.A.
    Liu W et al., 2012, Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A., J Med Chem
    Yoshino H et al., 2010, Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Bioorg Med Chem
    Yoshino H et al., 2010, Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Bioorg Med Chem
    Weiser PT et al., 2012, 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding., Bioorg Med Chem Lett
    Robinson et al., 2015, Integrative clinical genomics of advanced prostate cancer., Cell
    Fushimi C et al., 2018, A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma., Ann Oncol
    Madarová et al., 2001, Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide., Neoplasma
    McCourt et al., 2012, Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy., Clin. Cancer Res.
    McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica
    Fujii et al., 2004, Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells., Am. J. Physiol. Endocrinol. Metab.
    Sadar, 1999, Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways., J. Biol. Chem.
  • BICALUTAMIDE   FST

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14761877


    Sources:
    NCI

  • BICALUTAMIDE   CFLAR

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22623731


    Sources:
    CIViC

  • BICALUTAMIDE   KLK3

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10075669


    Sources:
    NCI

  • BICALUTAMIDE   CYP2B6

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9622849


    Sources:
    NCI

  • BICALUTAMIDE   BAX

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11845989


    Sources:
    NCI

  • BICALUTAMIDE   AR

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name bicalutimide,Casodex
    Novel drug target Established target
    Mechanism of Interaction Androgen Receptor antagonist

    PMIDs:
    10076535 11931851 10754148 12517791 11752352 10500149 22175694 21050768 20381361 23017882 26000489 29211833


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND CIViC TTD

  • TEND: BICALUTAMIDE

    • Version: 01-August-2011

    Alternate Names:
    BICALUTAMIDE Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1995

    Publications:

  • TdgClinicalTrial: BICALUTAMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: BICALUTAMIDE

    • Version: 14-September-2017

    Alternate Names:
    C1599 NCI drug code

    Drug Info:

    Publications:
    Madarová et al., 2001, Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide., Neoplasma
    McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica
    Fujii et al., 2004, Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells., Am. J. Physiol. Endocrinol. Metab.

  • DTC: BICALUTAMIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL409 ChEMBL Drug ID

    Drug Info:

    Publications:
    Yoshino H et al., 2010, Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Bioorg Med Chem
    Weiser PT et al., 2012, 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding., Bioorg Med Chem Lett
    Yoshino H et al., 2010, Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Bioorg Med Chem

  • CIViC: BICALUTAMIDE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hara et al., 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome., Cancer Res.
    Robinson et al., 2015, Integrative clinical genomics of advanced prostate cancer., Cell
    Fushimi C et al., 2018, A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma., Ann Oncol

  • TTD: Bicalutamide

    • Version: 2020.06.01

    Alternate Names:
    D0V9BD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL409

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL409

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21